These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

288 related items for PubMed ID: 36682938

  • 1. Adverse Events and Androgen Receptor Signaling Inhibitors in the Treatment of Prostate Cancer: A Systematic Review and Multivariate Network Meta-analysis.
    Cao B, Kim M, Reizine NM, Moreira DM.
    Eur Urol Oncol; 2023 Jun; 6(3):237-250. PubMed ID: 36682938
    [Abstract] [Full Text] [Related]

  • 2. The efficacy and adverse events of conventional and second-generation androgen receptor inhibitors for castration-resistant prostate cancer: A network meta-analysis.
    Zhang X, Zhang G, Wang J, Bi J.
    Front Endocrinol (Lausanne); 2023 Jun; 14():1131033. PubMed ID: 36843606
    [Abstract] [Full Text] [Related]

  • 3. Comparative efficacy of second-generation androgen receptor inhibitors for treating prostate cancer: A systematic review and network meta-analysis.
    Chen X, Wang Q, Pan Y, Wang S, Li Y, Zhang H, Xu M, Zhou H, Liu X.
    Front Endocrinol (Lausanne); 2023 Jun; 14():1134719. PubMed ID: 36967752
    [Abstract] [Full Text] [Related]

  • 4. Cardiovascular Events and Androgen Receptor Signaling Inhibitors in Advanced Prostate Cancer: A Systematic Review and Meta-Analysis.
    El-Taji O, Taktak S, Jones C, Brown M, Clarke N, Sachdeva A.
    JAMA Oncol; 2024 Jul 01; 10(7):874-884. PubMed ID: 38842801
    [Abstract] [Full Text] [Related]

  • 5. Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.
    Mori K, Mostafaei H, Pradere B, Motlagh RS, Quhal F, Laukhtina E, Schuettfort VM, Abufaraj M, Karakiewicz PI, Kimura T, Egawa S, Shariat SF.
    Int J Clin Oncol; 2020 Nov 01; 25(11):1892-1900. PubMed ID: 32924096
    [Abstract] [Full Text] [Related]

  • 6. The Hospitalization-Related Costs of Adverse Events for Novel Androgen Receptor Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer: An Indirect Comparison.
    Shore N, Jiang S, Garcia-Horton V, Terasawa E, Steffen D, Chin A, Ayyagari R, Partridge J, Waldeck AR.
    Adv Ther; 2022 Nov 01; 39(11):5025-5042. PubMed ID: 36028656
    [Abstract] [Full Text] [Related]

  • 7. Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer.
    Altavilla A, Casadei C, Lolli C, Menna C, Ravaglia G, Gurioli G, Farolfi A, Brighi N, Conteduca V, Burgio SL, Schepisi G, Rossi L, Gargiulo S, Lisotti I, De Giorgi U.
    Expert Opin Pharmacother; 2020 Dec 01; 21(17):2091-2099. PubMed ID: 32783772
    [Abstract] [Full Text] [Related]

  • 8. Androgen Receptor Inhibitors in Patients With Nonmetastatic Castration-Resistant Prostate Cancer.
    George DJ, Morgans AK, Constantinovici N, Khan N, Khan J, Chen G, Hlebec V, Shore ND.
    JAMA Netw Open; 2024 Aug 01; 7(8):e2429783. PubMed ID: 39190308
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cost-Utility Analysis of Darolutamide Combined with Androgen Deprivation Therapy for Patients with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer in China.
    Ming J, Wu Y, Han R, Xu X, Waldeck R, Hu S.
    Adv Ther; 2023 Mar 01; 40(3):1087-1103. PubMed ID: 36630046
    [Abstract] [Full Text] [Related]

  • 11. Effectiveness and tolerability of targeted drugs for the treatment of metastatic castration-resistant prostate cancer: a network meta-analysis of randomized controlled trials.
    Wang Y, Zhang H, Shen W, He P, Zhou Z.
    J Cancer Res Clin Oncol; 2018 Sep 01; 144(9):1751-1768. PubMed ID: 29797220
    [Abstract] [Full Text] [Related]

  • 12. Review of second-generation androgen receptor inhibitor therapies and their role in prostate cancer management.
    Jazayeri SB, Srivastava A, Shore N.
    Curr Opin Urol; 2022 May 01; 32(3):283-291. PubMed ID: 35552309
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Triplet therapy with androgen deprivation, docetaxel, and androgen receptor signalling inhibitors in metastatic castration-sensitive prostate cancer: A meta-analysis.
    Ciccarese C, Iacovelli R, Sternberg CN, Gillessen S, Tortora G, Fizazi K.
    Eur J Cancer; 2022 Sep 01; 173():276-284. PubMed ID: 35964470
    [Abstract] [Full Text] [Related]

  • 16. Comparison of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis.
    Wang L, Paller CJ, Hong H, De Felice A, Alexander GC, Brawley O.
    JAMA Oncol; 2021 Mar 01; 7(3):412-420. PubMed ID: 33443584
    [Abstract] [Full Text] [Related]

  • 17. Survival of Patients with Metastatic Prostate Cancer After Disease Progression on an Androgen Receptor Axis-Targeted Therapy Given in the Metastatic Castration-Sensitive Versus Metastatic Castration-Resistant Prostate Cancer Setting.
    Sayegh N, Tripathi N, Nussenzveig RH, Thomas VM, Tandar C, Goel D, Nordblad B, Sahu KK, Li H, L Maughan B, Agarwal N, Swami U.
    Eur Urol Focus; 2023 Jan 01; 9(1):106-109. PubMed ID: 35835693
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.